Integra LifeSciences (NASDAQ:IART) Downgraded to Buy Rating by Wall Street Zen

Wall Street Zen downgraded shares of Integra LifeSciences (NASDAQ:IART) from a strong-buy rating to a buy rating in a research report released on Saturday morning.

A number of other analysts have also commented on IART. Weiss Ratings raised shares of Integra LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, May 13th. BMO Capital Markets began coverage on shares of Integra LifeSciences in a research report on Wednesday, July 8th. They issued a “market perform” rating and a $19.00 target price on the stock. Truist Financial boosted their price target on shares of Integra LifeSciences from $14.00 to $19.00 and gave the company a “hold” rating in a report on Thursday. Citigroup restated a “neutral” rating and issued a $19.00 price target (up from $16.00) on shares of Integra LifeSciences in a research report on Wednesday, July 8th. Finally, Argus raised shares of Integra LifeSciences from a “hold” rating to a “buy” rating and set a $25.00 price objective for the company in a research note on Thursday, June 18th. One research analyst has rated the stock with a Buy rating, four have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Reduce” and a consensus price target of $18.33.

Integra LifeSciences Stock Performance

Shares of NASDAQ IART opened at $19.25 on Friday. The stock’s fifty day simple moving average is $16.91 and its 200 day simple moving average is $13.08. The stock has a market capitalization of $1.50 billion, a price-to-earnings ratio of -2.98, a PEG ratio of 1.33 and a beta of 1.22. The company has a quick ratio of 1.95, a current ratio of 3.38 and a debt-to-equity ratio of 1.75. Integra LifeSciences has a 52-week low of $8.70 and a 52-week high of $20.26.

Integra LifeSciences (NASDAQ:IART) last announced its earnings results on Tuesday, May 5th. The life sciences company reported $0.54 EPS for the quarter, beating the consensus estimate of $0.41 by $0.13. Integra LifeSciences had a positive return on equity of 17.42% and a negative net margin of 30.15%.The business had revenue of $391.92 million during the quarter, compared to the consensus estimate of $381.81 million. During the same period in the prior year, the business posted $0.41 earnings per share. Integra LifeSciences’s revenue was up 2.4% compared to the same quarter last year. Integra LifeSciences has set its FY 2026 guidance at 2.400-2.500 EPS and its Q2 2026 guidance at 0.440-0.520 EPS. As a group, sell-side analysts forecast that Integra LifeSciences will post 2.45 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Integra LifeSciences

Institutional investors and hedge funds have recently bought and sold shares of the business. SG Americas Securities LLC purchased a new stake in shares of Integra LifeSciences in the fourth quarter worth approximately $4,722,000. Hsbc Holdings PLC acquired a new stake in shares of Integra LifeSciences during the fourth quarter worth approximately $879,000. Tejara Capital Ltd grew its position in Integra LifeSciences by 42.6% during the fourth quarter. Tejara Capital Ltd now owns 171,813 shares of the life sciences company’s stock valued at $2,134,000 after purchasing an additional 51,300 shares in the last quarter. Assenagon Asset Management S.A. grew its position in Integra LifeSciences by 15.8% during the fourth quarter. Assenagon Asset Management S.A. now owns 526,302 shares of the life sciences company’s stock valued at $6,537,000 after purchasing an additional 71,950 shares in the last quarter. Finally, Systematic Financial Management LP increased its stake in Integra LifeSciences by 4.5% in the 4th quarter. Systematic Financial Management LP now owns 1,108,599 shares of the life sciences company’s stock valued at $13,769,000 after buying an additional 48,094 shares during the period. Hedge funds and other institutional investors own 84.78% of the company’s stock.

Integra LifeSciences Company Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.